Clinical Trial Update: Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 clinical trial evaluating ranibizumab for proliferative diabetic retinopathy requiring vitrectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Retina Associates, Kansas City | Conditions: Proliferative Diabetic Retinopathy | Phase 3 | Status: UNKNOWN